Sanofi

Sanofi

SNY

$41.62

Updated: 23/09/2026, 18:15:14

Market Cap
$99.93B
Sector
Healthcare
Industry
Drug Manufacturers - General
Country
FR
Stock valuation chart
One-year closing share-price history for SNY
Company Profile

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.

USD
NASDAQ
CEO: Belén Garijo López
Employees: 76,493
https://www.sanofi.com
Asset Summaries
Latest generated summaries for SNY

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for SNY.
Share price
$41.62
Market cap
$99.93B
Exchange
NASDAQ
Currency
USD
CEO
Belén Garijo López
Employees
76,493
IPO date
01/07/2002
Beta
0.278
Last dividend
$0.00
Day range
$41.57 – $41.96
52-week range
$40.89 – $52.68
1-day performance
-2.10%
1-year performance
1.78%
Current drawdown (1Y)
-21.00%
CIK
0001121404
CUSIP
80105N105
ISIN
US80105N1054
Created
07/12/2025, 14:19:26
Last update
23/09/2026, 18:15:14

Track Sanofi with an AI analyst

See which prediction-market events move SNY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to SNY from your Railway `news_articles` table.

FDA approves Sanofi's drug for stage 3 type 1 diabetes in children

Reuters • STOCK • 12/06/2026, 19:19:26

Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results

Zacks Investment Research • STOCK • 10/06/2026, 12:07:09

Sanofi ends Phase 3 riliprubart trial after weak interim results

Reuters • STOCK • 10/06/2026, 04:38:42

Sanofi to Stop Late-Stage Study of Immune-Disorder Drug

WSJ • STOCK • 10/06/2026, 04:28:00

Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

GlobeNewsWire • STOCK • 10/06/2026, 03:00:00

Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma

Zacks Investment Research • STOCK • 08/06/2026, 15:41:09

Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi

Business Wire • STOCK • 05/06/2026, 09:00:00

Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?

Zacks Investment Research • STOCK • 04/06/2026, 12:10:26

Press Release: Sanofi launches 2026 global employee stock purchase plan

GlobeNewsWire • STOCK • 04/06/2026, 06:07:00

FDA Grants Priority Review to SNY's Filing for Gaucher Disease Drug

Zacks Investment Research • STOCK • 29/05/2026, 13:01:14

Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease

GlobeNewsWire • STOCK • 28/05/2026, 03:00:00

Sanofi: Information concerning the total number of voting rights and shares - April 2026

GlobeNewsWire • STOCK • 19/05/2026, 14:37:00